21 CFR 17.54 - Deposit in the Treasury of the United States.

Status message

There is 1 rule appearing in the Federal Register for 21 CFR 17. View below or at eCFR (GPOAccess)
prev | next
§ 17.54 Deposit in the Treasury of the United States.
All amounts assessed pursuant to this part shall be delivered to the Director, Division of Financial Management (HFA-100), Food and Drug Administration, rm. 11-61, 5600 Fishers Lane, Rockville, MD 20857, and shall be deposited as miscellaneous receipts in the Treasury of the United States.

Title 21 published on 2013-04-01

The following are only the Rules published in the Federal Register after the published date of Title 21.

For a complete list of all Rules, Proposed Rules, and Notices view the Rulemaking tab.

  • 2014-02-03; vol. 79 # 22 - Monday, February 3, 2014
    1. 79 FR 6088 - Maximum Civil Money Penalty Amounts; Civil Money Penalty Complaints
      GPO FDSys XML | Text
      DEPARTMENT OF HEALTH AND HUMAN SERVICES, Food and Drug Administration
      Direct final rule.
      This rule is effective June 18, 2014, without further notice, unless FDA receives significant adverse comment by April 21, 2014. If we receive no timely significant adverse comments, we will publish a document in the Federal Register before May 19, 2014, confirming the effective date of the direct final rule. If we receive any timely significant adverse comments, we will publish a document in the Federal Register withdrawing this direct final rule before June 18, 2014.
      21 CFR Part 17

Title 21 published on 2013-04-01

The following are ALL rules, proposed rules, and notices (chronologically) published in the Federal Register relating to 21 CFR 17 after this date.

  • 2014-02-03; vol. 79 # 22 - Monday, February 3, 2014
    1. 79 FR 6088 - Maximum Civil Money Penalty Amounts; Civil Money Penalty Complaints
      GPO FDSys XML | Text
      DEPARTMENT OF HEALTH AND HUMAN SERVICES, Food and Drug Administration
      Direct final rule.
      This rule is effective June 18, 2014, without further notice, unless FDA receives significant adverse comment by April 21, 2014. If we receive no timely significant adverse comments, we will publish a document in the Federal Register before May 19, 2014, confirming the effective date of the direct final rule. If we receive any timely significant adverse comments, we will publish a document in the Federal Register withdrawing this direct final rule before June 18, 2014.
      21 CFR Part 17